This breast cancer preceptorship program, organized by Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO), offers intensive two-day training combining theoretical sessions and clinical rotations.
It addresses therapeutic strategies for early-stage and metastatic HR+/HER2- breast cancer, covering international guidelines, biomarkers, and precision medicine.
The program delves into molecular diagnosis, tissue and liquid biopsies, and relevant mutations (ESR1, PIK3CA, BRCA1/2) and their impact on clinical decision-making.
Additionally, it includes discussions on clinical cases, patient navigation, side-effect management, and the analysis of real-world studies in oncology.